Matoga Mitch M, Rosenberg Nora E, Stanley Christopher C, LaCourse Sylvia, Munthali Charles K, Nsona Dominic P, Haac Bryce, Hoffman Irving, Hosseinipour Mina C
University of North Carolina Project, Lilongwe, Malawi.
University of North Carolina, Chapel Hill, North Carolina, United States of America.
PLoS One. 2018 Feb 7;13(2):e0191944. doi: 10.1371/journal.pone.0191944. eCollection 2018.
In the era of increased access to HIV testing and antiretroviral treatment (ART), the impact of HIV and ART status on inpatient mortality in Malawi is unknown.
We prospectively followed adult inpatients at Kamuzu Central Hospital medical wards in Lilongwe, Malawi, between 2011 and 2012, to evaluate causes of mortality, and the impact of HIV and ART status on mortality. We divided the study population into five categories: HIV-negative, new HIV-positive, ART-naïve patients, new ART-initiators, and ART-experienced. We used multivariate binomial regression models to compare risk of death between categories.
Among 2911 admitted patients the mean age was 38.5 years, and 50% were women. Eighty-one percent (81%) of patients had a known HIV status at the time of discharge or death. Mortality was 19.4% and varied between 13.9% (HIV-negative patients) and 32.9% (HIV-positive patients on ART ≤1 year). In multivariable analyses adjusted for age, sex and leading causes of mortality, being new HIV-positive (RR = 1.64 95% CI: 1.16-2.32), ART-naive (RR = 2.28 95% CI: 1.66-2.32) or being a new ART-initiator (RR = 2.41 95% CI: 1.85-3.14) were associated with elevated risk of mortality compared to HIV-negative patients. ART-experienced patients had comparable mortality (RR = 1.33 95% CI: 0.94-1.88) to HIV-negative patients.
HIV related mortality remains high among medical inpatients, especially among HIV-positive patients who recently initiated ART or have not started ART yet.
在获得艾滋病毒检测和抗逆转录病毒治疗(ART)机会增加的时代,艾滋病毒和抗逆转录病毒治疗状态对马拉维住院患者死亡率的影响尚不清楚。
2011年至2012年期间,我们对马拉维利隆圭卡木祖中央医院内科病房的成年住院患者进行了前瞻性跟踪,以评估死亡原因以及艾滋病毒和抗逆转录病毒治疗状态对死亡率的影响。我们将研究人群分为五类:艾滋病毒阴性、新确诊艾滋病毒阳性、未接受抗逆转录病毒治疗的患者、开始接受抗逆转录病毒治疗的新患者以及有抗逆转录病毒治疗经验的患者。我们使用多变量二项式回归模型比较各类别之间的死亡风险。
在2911名入院患者中,平均年龄为38.5岁,50%为女性。81%的患者在出院或死亡时已知艾滋病毒感染状况。死亡率为19.4%,在13.9%(艾滋病毒阴性患者)至32.9%(接受抗逆转录病毒治疗≤1年的艾滋病毒阳性患者)之间有所不同。在对年龄、性别和主要死亡原因进行调整的多变量分析中,与艾滋病毒阴性患者相比,新确诊艾滋病毒阳性(相对风险=1.64,95%置信区间:1.16-2.32)、未接受抗逆转录病毒治疗(相对风险=2.28,95%置信区间:1.66-2.32)或开始接受抗逆转录病毒治疗的新患者(相对风险=2.41,95%置信区间:1.85-3.14)的死亡风险升高。有抗逆转录病毒治疗经验的患者与艾滋病毒阴性患者的死亡率相当(相对风险=1.33,95%置信区间:0.94-1.88)。
在内科住院患者中,与艾滋病毒相关的死亡率仍然很高,尤其是在最近开始接受抗逆转录病毒治疗或尚未开始接受抗逆转录病毒治疗的艾滋病毒阳性患者中。